Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
HRTX - Heron Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$6.67
DETAILS
HIGH:
$9.00
LOW:
$5.00
MEDIAN:
$6.00
CONSENSUS:
$6.67
UPSIDE:
676.67%
Stock News
Heron Therapeutics Q1 Earnings Call Highlights
Heron Therapeutics NASDAQ: HRTX said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving momentum exiting the quarter.
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2026, and highlighted recent corporate updates.
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, May 11, 2026, at 8:30 a.m. ET to report first quarter 2026 financial results and discuss recent business highlights.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
– ZYNRELEF ® and APONVIE ® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise – Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and Adjusted EBITDA of $10 to $20 Million CARY, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and highlighted recent corporate updates.
Heron: Near The Bottom Of A Trading Range Despite Positives
HRTX has reported preliminary Q4'25 net revenues, with Zynrelef experiencing a breakout quarter. Aponvie sales are also still growing, with the acute care franchise being able to offset declines in the oncology care franchise. HRTX recently dealt with its 2026 convertible notes, although the company does now have debt maturing in 2030 and 2031.
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, February 26, 2026, at 8:30 a.m. ET to report fourth quarter and full year 2025 financial results and discuss recent business highlights.
New York State Common Retirement Fund Buys 816,671 Shares of Heron Therapeutics, Inc. $HRTX
New York State Common Retirement Fund raised its stake in Heron Therapeutics, Inc. (NASDAQ: HRTX) by 46.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,576,716 shares of the biotechnology company's stock after purchasing an additional 816,671 shares
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast
Heron Therapeutics (NASDAQ: HRTX - Get Free Report) and Enliven Therapeutics (NASDAQ: ELVN - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Insider and Institutional Ownership 80.0% of Heron
Price Targets
Heron Therapeutics initiated with a Buy at H.C. Wainwright
$6.00
(was $2.12)
Brandon Folkes
·
H.C. Wainwright
Northland Reiterates Outperform Rating on Heron Therapeutics (HRTX)
$9.00
(was $3.22)
Carl Byrnes
·
Northland Securities
Heron Therapeutics (HRTX) PT Raised to $5 at Needham to reflect strong sales trends
$5.00
(was $3.01)
Serge Belanger
·
Needham